The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT.
 
Emre Koca
No Relationships to Disclose
 
Polly Ann Niravath
Honoraria - Genomic Health
Consulting or Advisory Role - Immunomedics; Novartis
 
Joe Ensor
Consulting or Advisory Role - Aetna; StatAnalytics IDD
 
Tejal Amar Patel
No Relationships to Disclose
 
Xiaoxian Li
No Relationships to Disclose
 
Pej Hemati
No Relationships to Disclose
 
Helen Wong
No Relationships to Disclose
 
Wei Qian
No Relationships to Disclose
 
Toniva Boone
No Relationships to Disclose
 
Jing Zhao
No Relationships to Disclose
 
Priya V. Ramshesh
No Relationships to Disclose
 
Adam Louis Cohen
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Cantex (Inst); Daiichi Sankyo (Inst); Diffusion Pharmaceuticals (Inst); Lilly (Inst); Merrimack (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Asha Murthy
No Relationships to Disclose
 
Sindhu Nair
No Relationships to Disclose
 
Jorge German Darcourt
No Relationships to Disclose
 
Anna Belcheva
No Relationships to Disclose
 
Virginia G. Kaklamani
Honoraria - Celgene; Eisai; Genentech; Genomic Health; Novartis; Pfizer
Speakers' Bureau - Celgene; Eisai; Genentech
Research Funding - Eisai
 
Jenny Chee Ning Chang
Consulting or Advisory Role - Celgene; Genentech
Travel, Accommodations, Expenses - Celgene; Genentech